uniQure N.V. (QURE) dropped 50.27% to $33.66, down $34.03, after announcing that the FDA intends to place a clinical hold on its AMT-130 Huntington's disease program.
The update follows discussions with the agency regarding previously observed MRI findings, and the company expects the hold to be formalized in the coming days.
uniQure said it will work closely with the FDA to address regulatory questions and determine next steps for the program.
QURE opened at $61.49, reached a high of $62.60 and a low of $32.78, compared to a previous close of $67.69 on the NasdaqGS. Trading volume surpassed 12 million shares, far above the average of 430,000. The stock's 52-week range is $31.15 - $83.35.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.